Treatment of Childhood Headache with Dihydroergotamine Mesylate


  • Steven L. Linder M.D.

    Assistant Clinical Professor, Corresponding author
    1. Dallas Pediatric Neurology Associates, Southwestern Medical School, University of Texas Health Science Center at Dallas, Medical City Dallas Hospital, Dallas, TX
    Search for more papers by this author

Steven L. Linder, M.D., Dallas Pediatric Neurology Associates, 12801 North Central Expressway, North Central Plaza III, Suite 580, Dallas, TX 75243-1708



This study was undertaken to determine whether pediatric patients with migraine without aura who have failed standard outpatient regimens including intravenous dihydroergotamine mesylate (DHE) in conjunction with oral metoclopramide would respond to an inpatient treatment protocol of intravenous DHE and oral metoclopramide. Thirty patients were evaluated in this study which was an open label, retrospective review of treatment. Independent of the duration of the refractory migraine, 80% of the patients responded to the protocol with only minimal side effect. The dose of DHE mesylate ranged from 0.1 to 0.5 mg. The dose of DHE is lower than is typically utilized in standard adult protocols. The patients received an average of five doses of DHE.